TY -的T1 - 1 b期临床试验与多发性硬化和抗原耐受性树突状Neuromyelitis视:安全性和免疫效果(P2.330) JF -神经学乔-神经学六世- 88 - 16补充SP - P2.330盟Irati Zubizarreta Nafarrate AU -乔治娜Florez盟吉玛维拉AU -拉奎尔大头鱼盟卡西班牙AU -丹尼尔·贝尼特斯盟-莎首页拉Varea AU -琼艾伯特Arnaiz AU -阿尔伯特Saiz盟Pablo Villoslada Diaz Y1 - 2017/04/18 UR - //www.ez-admanager.com/content/88/16_Supplement/P2.330.abstract N2 -目的:评估的安全性和免疫效果抗原特异性治疗多发性硬化症(MS)和视Neuromyelitis(动)。背景:抗原特异性耐受性树突状细胞免疫治疗已经显示出女士的功效在动物模型中,其安全性和有效性仍不清楚。设计/方法:9例(6和3动病人女士)已经包含在一个提升剂量抗原特异性耐受性树突状细胞的协议。树突细胞来源于单核细胞分离后leukopheresis和耐受化与地塞米松诱导。疾病相关肽(MOG1-20 MOG35-55、MBP13-32 mbp83 - 99, mbp111 - 129, mbp146 - 17188金宝慱官网下载0, plp139 - 154,为63 - 76 MS和AQP4动)耐受化过程中被添加。每两周临床及免疫学评估进行了3个月。主要终点是安全性和次要端点免疫标记的变化和临床活动(复发或残疾(eds))的变化。免疫学的研究包括增生性化验、有关酶联免疫斑点IL10,细胞因子的生产与IL17 IFNg和外围细胞通过流式细胞术种群动态。结果:直到现在没有观察到相关的副作用。我们发现一个开关通过流式细胞术Th2反应。ELISPOT化验和扩散分析表明IL10的增加和减少IFNg生产。结论:抗原特异性治疗耐受性直流似乎与动女士和患者安全的免疫支持功能治疗的耐受性的作用。披露:博士Zubizarreta Nafarrate没有披露。Florez博士没有披露。 Dr. Vila has nothing to disclose. Dr. Cabezón has nothing to disclose. Dr. España has nothing to disclose. Dr. Benitez has nothing to disclose. Dr. Varea has nothing to disclose. Dr. Arnaiz has nothing to disclose. Dr. Saiz has received personal compensation for consulting services and speaking from Bayer-Schering, Merck-Serono, Biogen Idec, Sanofi-Aventis, Teva Pharmaceutical Industries Ltd and Novartis as a consultant and speaker. Dr. Villoslada has received personal compensation for activities with Roche and Novartis as a consultant. ER -